Beitner 1996.

Methods	Randomised controlled trial This study was conducted at a single centre in Sweden The study probably was not blinded
Participants	30 consecutive participants with different dermatological hand dermatoses including pustulosis palmoplantaris (n = 5), psoriasis (n = 1), tylotic eczema (n = 4), atopic eczema (n = 3), dyshidrotic eczema (n = 1), allergic eczema (n = 7), and non‐allergic eczema (n = 1), both allergic eczema and dyshidrotic (n = 2) Dropouts: 6 Inclusion and exclusion criteria were not stated
Interventions	Intervention • Clobetsaol propionate (Dermovate Glaxo) solution under occlusion with a hydrocolloid dressing twice a week for the first 2 weeks and once a week for the next 2 weeks • Clobetasol propionate ointment under occlusion with a hydrocolloid dressing twice a week for the first 2 weeks and once a week for the next 2 weeks Follow‐up included a visit 12 weeks after the start of treatment
Outcomes	Primary outcomes of the trial Not stated Other outcomes Symptom severity for itching, erythema, infiltration, and scaling, each graded on a 4‐point scale (0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe) Participant‐rated severity of itch on a visual analogue scale (VAS) Vesicles/pustules: absent or present Relapse within 12 weeks Adverse events
Notes	Study results for hand eczema participants were not presented separately, and we were unable to obtain additional data from the study author This study was published as a very concise letter to the editor, and a lot was uncertain, for example, visits and outcome parameters